Trials / Completed
CompletedNCT01723982
Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions
A Randomised, Placebo-controlled, Double-blind, Parallel Groups, Multinational, Multicentre Trial Assessing the Effect of Barusiban Administered Subcutaneously on the Day of Transfer on Implantation and Pregnancy Rates in IVF/ICSI Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 256 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years – 37 Years
- Healthy volunteers
- Not accepted
Summary
This trial investigates the effects of FE 200440 compared to placebo on implantation rate in women undergoing IVF/ICSI treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Barusiban (FE 200440) | |
| DRUG | Placebo Comparator |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2014-10-01
- Completion
- 2015-05-01
- First posted
- 2012-11-08
- Last updated
- 2015-06-16
Locations
14 sites across 6 countries: Australia, Belgium, Canada, Czechia, Poland, Spain
Source: ClinicalTrials.gov record NCT01723982. Inclusion in this directory is not an endorsement.